ETNB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ETNB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-05), 89bio's share price is $8.115. 89bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.70. Hence, 89bio's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for 89bio's Price-to-Free-Cash-Flow or its related term are showing as below:
89bio's Free Cash Flow per Share for the three months ended in Mar. 2024 was $-0.41. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-1.70.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 14.30% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 16.70% per year.
During the past 6 years, 89bio's highest 3-Year average Free Cash Flow per Share Growth Rate was 40.20% per year. The lowest was -11.90% per year. And the median was 14.30% per year.
The historical data trend for 89bio's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
89bio Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
89bio Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, 89bio's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, 89bio's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where 89bio's Price-to-Free-Cash-Flow falls into.
89bio's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 8.115 | / | -1.701 | |
= | N/A |
89bio's Share Price of today is $8.115.
89bio's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.70.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
89bio (NAS:ETNB) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of 89bio's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Kathleen Laporte | director | |
Rohan Palekar | director, officer: Chief Executive Officer | 201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105 |
Atkinson Edward Morrow Iii | director | C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104 |
Quoc Le-nguyen | officer: See Remarks | 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
Ryan Martins | officer: Chief Financial Officer | 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
Michael R Hayden | director | C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Nexus Fund, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ram Waisbourd | officer: See Remarks | 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
Orbimed Advisors Llc | director, 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Gregory Grunberg | director, 10 percent owner | 100 BEAVER STREET, WALTHAM MA 02453 |
Anat Naschitz | director, 10 percent owner | 535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105 |
Longitude Capital Partners Iii, Llc | 10 percent owner | 800 EL CAMINO, SUITE 220, MENLO PARK CA 94025 |
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
Steven Altschuler | director | MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026 |
From GuruFocus
By GlobeNewswire • 11-12-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GlobeNewswire • 06-24-2023
By GlobeNewswire • 06-24-2023
By sperokesalga sperokesalga • 05-02-2023
By GuruFocus Research GuruFocus Editor • 02-18-2023
By Marketwired • 10-03-2023
By sperokesalga sperokesalga • 06-07-2023
By Value_Insider Value_Insider • 10-13-2022
By GlobeNewswire GlobeNewswire • 11-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.